Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with DEPO as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.43%||First Trust DJ Select MicroCap ETF (FDM)||-0.03 (-0.09%)|
|0.38%||PowerShares Zacks Micro Cap (PZI)||-0.32 (-1.98%)|
|0.37%||iShares Microcap ETF (IWC)||-5.03 (-6.26%)|
Company Description (as filed with the SEC)
Depomed is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The products that comprise our current specialty pharmaceutical business are Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia (PHN) that we launched in October 2011, CAMBIA® (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks that we acquired in December 2013, Zipsor® (diclofenac potassium) liquid filled capsules, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain that we acquired in June 2012, and Lazanda® (fentanyl) nasal spray, a product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain, that we acquired in July 2013. ... More ...
Where does DEPO fit in the risk graph?
|Annual EPS Est:||$0.17|
|Quarterly EPS Est:||-0.09|